Worcester Firm Unveils Cancer Vaccine Study
A Worcester company has presented findings on a vaccine for certain types of cancer.
Antigen Express Inc., a wholly-owned subsidiary of Worcester-based Generex Biotechnology Corp., presented the study, which includes pre-clinical findings on a vaccine for human papilloma virus-induced cancers, Monday at the ongoing annual meeting of the American Association for Cancer Research in Denver.
Antigen has identified and modified a fragment of the HPV protein to enhance the production of cells that kill HPV target cells. The company said widespread use of existing HPV vaccines has been hindered by their expense.
Guardisil, a vaccine marketed by drug maker Wyeth, protects against HPV. Antigen's vaccine prevents cancer even if HPV is present.
No vaccine exists for patients with cervical or other cancers induced by HPV. Antigen is currently conducting trials of a similarly modified protein that may be able to kill breast, prostate and ovarian cancer cells.
Generex develops drug delivery systems that allow drugs typically given by injection to be taken orally and absorbed by the inner lining of the mouth.
WBJ Web Partners
Most Recent
Most Recent
0 Comments